We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY SIRONA Inc. (XRAY - Free Report) recently announced preliminary revenues for full-year 2022. The company also announced encouraging long-term growth prospect and earnings growth projection.
Per the preliminary report, the company expects its total revenues to be at the higher-end of the guided range of $3.85 billion to $3.88 billion. The Zacks Consensus Estimate of $3.87 billion lies within the company’s guided range. The preliminary revenues for 2022 indicate a decline of 8.7-9.4% from the year-ago period.
XRAY anticipates adjusted earnings per share (EPS) between its guided range of $1.90 and $2.00. The Zacks Consensus Estimate of $1.96 lies within the company’s guided range.
Based on the company’s full-year guidance, its fourth quarter revenues should lie within the range of $911 million to $941 million. The Zacks Consensus Estimate of $927.2 million lies within the range.
During the third quarter earnings call, DENTSPLY SIRONA’s management stated that it is encouraged by the double-digit growth in clear aligners, solid performance in Europe, and continued strong demand for Imaging equipment. The trend is likely to have continued in the fourth quarter. However, continued macroeconomic headwinds, including foreign currency impacts, global supply chain challenges, and regional softness in China and the United States are likely to have offset the aforementioned robust growth.
Apart from the full-year results, DENTSPLY SIRONA provided its plans to drive growth over the next three years. The company presented these plans at the J.P. Morgan Healthcare Conference, held on Jan 11. The company stated that positive demographics trend, rising globalization and continued growth in esthetic industry will be the key macro factors that will drive its top-line going forward.
Moreover, the adoption of digital technologies and rising awareness for oral healthcare, along with improving efficiency of dental workflows will drive revenues for the industry, including XRAY. The company is integrating workflows through software into one digital platform to provide ease of access. It is also strengthening its product portfolio with continued innovation.
DENTSPLY SIRONA has a complete dental portfolio, which targets a large and growing industry. The company is implementing several measures to bring meaningful improvements in its earnings by the end of 2025. It expects to exit 2025 with earnings of $3.00 per share.
A Brief FY22 Analysis
DENTSPLY SIRONA recorded nearly $4 billion in sales during 2022. The company generated approximately 40% of its sales from Europe, 35% from the U.S. market and 25% from the rest of the world. Key product categories in descending order of revenue-share are Endodontic & Restorative, Equipment & Instruments, Implant Solutions, CAD/CAM, Other Consumable and Aligners. The company ended 2022 with leading positions in categories like Endodontic & Restorative, CAD/CAM and Preventive consumables.
DENTSPLY SIRONA has spent approximately 4% of its sales in Research and Development, and capital expenditure, each during 2022.
Price Performance
Shares of DENTSPLY SIRONA have declined 32.3% in the past year compared with the industry’s 4.7% and the S&P 500’s 15.7% decline.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, DENTSPLY SIRONA carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Cardinal Health (CAH - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.96%.
AMN Healthcare has declined 4.2% compared with the industry’s 24.5% decrease in the past year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.7%. CAH’s earnings surpassed estimates in two of the trailing four quarters and missed the same in two, the average beat being 3.04%.
Cardinal Health has gained 44.8% against the industry’s 4.6% decline over the past year.
Merit Medical, sporting a Zacks Rank #1 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.35 %.
Merit Medical has gained 21.7% against the industry’s 4.6% decline over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates
DENTSPLY SIRONA Inc. (XRAY - Free Report) recently announced preliminary revenues for full-year 2022. The company also announced encouraging long-term growth prospect and earnings growth projection.
The company is expected to release its fourth-quarter results next month.
Per the preliminary report, the company expects its total revenues to be at the higher-end of the guided range of $3.85 billion to $3.88 billion. The Zacks Consensus Estimate of $3.87 billion lies within the company’s guided range. The preliminary revenues for 2022 indicate a decline of 8.7-9.4% from the year-ago period.
XRAY anticipates adjusted earnings per share (EPS) between its guided range of $1.90 and $2.00. The Zacks Consensus Estimate of $1.96 lies within the company’s guided range.
Based on the company’s full-year guidance, its fourth quarter revenues should lie within the range of $911 million to $941 million. The Zacks Consensus Estimate of $927.2 million lies within the range.
During the third quarter earnings call, DENTSPLY SIRONA’s management stated that it is encouraged by the double-digit growth in clear aligners, solid performance in Europe, and continued strong demand for Imaging equipment. The trend is likely to have continued in the fourth quarter. However, continued macroeconomic headwinds, including foreign currency impacts, global supply chain challenges, and regional softness in China and the United States are likely to have offset the aforementioned robust growth.
DENTSPLY SIRONA Inc. Price
DENTSPLY SIRONA Inc. price | DENTSPLY SIRONA Inc. Quote
Long-Term Update
Apart from the full-year results, DENTSPLY SIRONA provided its plans to drive growth over the next three years. The company presented these plans at the J.P. Morgan Healthcare Conference, held on Jan 11. The company stated that positive demographics trend, rising globalization and continued growth in esthetic industry will be the key macro factors that will drive its top-line going forward.
Moreover, the adoption of digital technologies and rising awareness for oral healthcare, along with improving efficiency of dental workflows will drive revenues for the industry, including XRAY. The company is integrating workflows through software into one digital platform to provide ease of access. It is also strengthening its product portfolio with continued innovation.
DENTSPLY SIRONA has a complete dental portfolio, which targets a large and growing industry. The company is implementing several measures to bring meaningful improvements in its earnings by the end of 2025. It expects to exit 2025 with earnings of $3.00 per share.
A Brief FY22 Analysis
DENTSPLY SIRONA recorded nearly $4 billion in sales during 2022. The company generated approximately 40% of its sales from Europe, 35% from the U.S. market and 25% from the rest of the world. Key product categories in descending order of revenue-share are Endodontic & Restorative, Equipment & Instruments, Implant Solutions, CAD/CAM, Other Consumable and Aligners. The company ended 2022 with leading positions in categories like Endodontic & Restorative, CAD/CAM and Preventive consumables.
DENTSPLY SIRONA has spent approximately 4% of its sales in Research and Development, and capital expenditure, each during 2022.
Price Performance
Shares of DENTSPLY SIRONA have declined 32.3% in the past year compared with the industry’s 4.7% and the S&P 500’s 15.7% decline.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, DENTSPLY SIRONA carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Cardinal Health (CAH - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.96%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has declined 4.2% compared with the industry’s 24.5% decrease in the past year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.7%. CAH’s earnings surpassed estimates in two of the trailing four quarters and missed the same in two, the average beat being 3.04%.
Cardinal Health has gained 44.8% against the industry’s 4.6% decline over the past year.
Merit Medical, sporting a Zacks Rank #1 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.35 %.
Merit Medical has gained 21.7% against the industry’s 4.6% decline over the past year.